Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

Compare

571 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRNX Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Crinetics

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$67.42

▲(146.24% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $67.42 with a high forecast of $97.00 and a low forecast of $27.00. The average price target represents a 146.24% change from the last price of $27.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","44":"$44","62":"$62","80":"$80","98":"$98"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,44,62,80,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,33.16,38.48,43.8,49.12,54.44,59.75999999999999,65.08,70.39999999999999,75.72,81.03999999999999,86.36,91.67999999999999,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,30.884615384615383,33.92923076923077,36.973846153846154,40.01846153846154,43.06307692307692,46.107692307692304,49.15230769230769,52.19692307692307,55.241538461538454,58.28615384615384,61.33076923076922,64.37538461538462,{"y":67.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,27.775384615384617,27.71076923076923,27.646153846153847,27.58153846153846,27.516923076923078,27.45230769230769,27.38769230769231,27.323076923076922,27.25846153846154,27.193846153846152,27.12923076923077,27.064615384615383,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$97.00

Average Price Target$67.42

Lowest Price Target$27.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Schwartz

Leerink Partners

$80

Buy

192.18%

Upside

Reiterated

08/11/25

Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones

Jonathan Wolleben

Citizens JMP

$90→$86

Buy

214.10%

Upside

Reiterated

08/11/25

Crinetics price target lowered to $86 from $90 at Citizens JMPCrinetics price target lowered to $86 from $90 at Citizens JMP

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$72

Buy

162.97%

Upside

Reiterated

08/11/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISIEarnings Overload SMID Biotech Week in Review

Douglas Tsao

H.C. Wainwright

$69→$81

Buy

195.84%

Upside

Reiterated

08/08/25

H.C. Wainwright Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Catherine Novack

JonesTrading

$71→$65

Buy

137.40%

Upside

Reiterated

08/08/25

JonesTrading Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

David Lebowitz

Citi

$63→$60

Buy

119.14%

Upside

Reiterated

08/08/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Citi

Yasmeen Rahimi

Piper Sandler

$97

Buy

254.27%

Upside

Reiterated

08/08/25

Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)

Cory Jubinville, PhD

LifeSci Capital

$82

Buy

199.49%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (NYSE: ZBH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Alex Thompson CFA

Stifel Nicolaus

$60→$58

Buy

111.83%

Upside

Reiterated

08/08/25

Stifel Nicolaus Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Stifel analyst Alex Thompson lowered the price target on Crinetics (NASDAQ: CRNX) to $58.00 (from $60.00) while maintaining a Buy rating.

Maxwell Skor

Morgan Stanley

$65

Buy

137.40%

Upside

Reiterated

08/08/25

Morgan Stanley Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/07/25

Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch

Richard Law CFA

Goldman Sachs

$36

Hold

31.48%

Upside

Initiated

07/10/25

Crinetics Pharmaceuticals (CRNX) Has a New Rating from Goldman Sachs

Jessica Fye

J.P. Morgan

$57→$53

Buy

93.57%

Upside

Reiterated

03/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joshua Schimmer

Cantor Fitzgerald

$90→$100

Buy

265.23%

Upside

Reiterated

02/28/25

Crinetics (CRNX) PT Raised to $100 at Cantor FitzgeraldCantor Fitzgerald analyst Josh Schimmer raised the price target on Crinetics (NASDAQ: CRNX) to $100.00 (from $90.00) while maintaining a Overweight rating.

Andy Chen

Wolfe Research

―

Hold

―

Initiated

02/03/25

Crinetics initiated with a Peer Perform at Wolfe ResearchCrinetics initiated with a Peer Perform at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Schwartz

Leerink Partners

$80

Buy

192.18%

Upside

Reiterated

08/11/25

Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones

Jonathan Wolleben

Citizens JMP

$90→$86

Buy

214.10%

Upside

Reiterated

08/11/25

Crinetics price target lowered to $86 from $90 at Citizens JMPCrinetics price target lowered to $86 from $90 at Citizens JMP

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$72

Buy

162.97%

Upside

Reiterated

08/11/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISIEarnings Overload SMID Biotech Week in Review

Douglas Tsao

H.C. Wainwright

$69→$81

Buy

195.84%

Upside

Reiterated

08/08/25

H.C. Wainwright Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Catherine Novack

JonesTrading

$71→$65

Buy

137.40%

Upside

Reiterated

08/08/25

JonesTrading Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

David Lebowitz

Citi

$63→$60

Buy

119.14%

Upside

Reiterated

08/08/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Citi

Yasmeen Rahimi

Piper Sandler

$97

Buy

254.27%

Upside

Reiterated

08/08/25

Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)

Cory Jubinville, PhD

LifeSci Capital

$82

Buy

199.49%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (NYSE: ZBH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Alex Thompson CFA

Stifel Nicolaus

$60→$58

Buy

111.83%

Upside

Reiterated

08/08/25

Maxwell Skor

Morgan Stanley

$65

Buy

137.40%

Upside

Reiterated

08/08/25

Morgan Stanley Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/07/25

Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch

Richard Law CFA

Goldman Sachs

$36

Hold

31.48%

Upside

Initiated

07/10/25

Crinetics Pharmaceuticals (CRNX) Has a New Rating from Goldman Sachs

Jessica Fye

J.P. Morgan

$57→$53

Buy

93.57%

Upside

Reiterated

03/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joshua Schimmer

Cantor Fitzgerald

$90→$100

Buy

265.23%

Upside

Reiterated

02/28/25

Andy Chen

Wolfe Research

―

Hold

―

Initiated

02/03/25

Crinetics initiated with a Peer Perform at Wolfe ResearchCrinetics initiated with a Peer Perform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

1 Month

xxx

Success Rate

8/13 ratings generated profit

Average Return

+10.10%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +10.10% per trade.

3 Months

xxx

Success Rate

10/13 ratings generated profit

Average Return

+20.54%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +20.54% per trade.

1 Year

Brian SkorneyRobert W. Baird

Success Rate

7/13 ratings generated profit

Average Return

+55.34%

reiterated a buy rating 9 months ago

Copying Brian Skorney's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +55.34% per trade.

2 Years

xxx

Success Rate

18/31 ratings generated profit

Average Return

+48.98%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.06% of your transactions generating a profit, with an average return of +48.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 25 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 67.42.

Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.23 with a range of -$1.44 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $617.00K with a range of $0.00 to $2.70M. The previous quarter’s sales results were $1.03M. CRNX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 67.42.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharmaceuticals has 146.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Crinetics Pharmaceuticals’s price target?

The average price target for Crinetics Pharmaceuticals is 67.42. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $97.00 ,the lowest forecast is $27.00. The average price target represents 146.24% Increase from the current price of $27.38.

What do analysts say about Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts